Blog - Page 3865 of 5178

MondayNov 03, 2008 4:41 am

BioSpecifics Technologies Corp. (OTC BB: BSTC)

BioSpecifics Technologies Corp. (OTC BB: BSTC), a biopharmaceutical company, has developed and licensed injectable collagenase for three clinical indications. Their development and licensing agreement with Auxilium Pharmaceuticals (Nasdaq GM: AUXL) is for clinical indications in Dupuytren’s disease, Peyronie’s disease and frozen shoulder (adhesive capsulitis). Currently, all of their efforts are focused on the future development and commercialization of injectable collagenase products. For further information, visit the Company's web site at www.biospecifics.com.

MondayNov 03, 2008 4:41 am

Orthovita, Inc. (NASDAQ: VITA)

Orthovita, Inc. (NASDAQ: VITA), a novel spine/orthopaedic surgical biomaterials company, is focused on providing progressive bone regeneration and soft tissue healing technologies. The company’s expertise lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Currently, Orthovita has several key commercial product platforms including: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems. For further information, visit the Company's web site at www.orthovita.com.

MondayNov 03, 2008 4:40 am

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company, is committed to developing products for female sexual health, menopause, contraception and male hypogonadism. Lead products within their produce line include LibiGel® (transdermal testosterone gel), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment); and Elestrin™ (estradiol gel) which has been developed through FDA approval. For further information, visit the Company's web site at www.biosantepharma.com.

MondayNov 03, 2008 4:40 am

Origin Agritech Limited (NASDAQ: SEED)

Origin Agritech Limited (NASDAQ: SEED), a leading agricultural biotechnology company and a top player in seed industry, specializes in researching and developing, producing, selling and distributing agricultural crop seeds. The Company's major seed products are corn, rice, cotton and canola. Located in Beijing, China, the company is focused on crop improvement and utilizes biotechnology to achieve their goals. For further information, visit the company website at: www.originagritech.com.

MondayNov 03, 2008 4:39 am

Orexigen Therapeutics, Inc. (NASDAQ: OREX)

Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company, has focused their efforts on the development of pharmaceutical product candidates designed to treat obesity and other central nervous system-related disorders. The company’s lead combination product candidates targeted for obesity include: Contrave®, which is in Phase 3 clinical trials; and Empatic™, which is in the later stages of Phase 2 clinical development. For further information, visit the Company's web site at www.orexigen.com.

MondayNov 03, 2008 4:39 am

Orko Silver Corp. (TSX: OK CN)

Orko Silver Corp. (TSX: OK CN) is focused on exploring and developing for silver and gold within the borders of Mexico. The Company has a large land position in Durango State, a historically prolific silver mining region located along the Sierra Madre Occidental Mountains and is involved in three main projects, La Preciosa, Santa Monica and San Juan. The company also owns a 100% interest in the La Preciosa Project and the adjacent Santa Monica Project; in addition to a 75% interest in a Joint Venture on the adjacent San Juan property. For further information, visit the Company's web site…

MondayNov 03, 2008 4:39 am

Bionovo, Inc. (NASDAQ: BNVI)

Bionovo, Inc. (NASDAQ: BNVI), a drug discovery and development company, has their focus on developing safe and effective drugs to treat unmet medical needs in women’s health and cancer. Their aim is to improve the quality of women’s health and defeat life-threatening cancers. The company has a diverse pipeline of preclinical drug candidates to address both women’s health and cancer, and have identified or begun preclinical work on several multiple drug candidates for a variety of indications. For further information, visit the Company's web site at www.bionovo.com.

MondayNov 03, 2008 4:38 am

Oramed Pharmaceuticals Inc. (OTC BB: ORMP)

Oramed Pharmaceuticals Inc. (OTC BB: ORMP), a commercial drug development company, is applying proprietary expertise in integrative pharmacology to potentially discover new uses for drug candidates. Currently, the company is committing their efforts to developing certain compounds for new uses. Compounds in Ore’s development pipeline include: romazarit (for metabolic disorders), tiapamil (for treatment of diseases of the central nervous system), and GL1001 (for inflammatory bowel disease). For further information, visit the Company's web site at www.oramed.com.

MondayNov 03, 2008 4:38 am

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company, has focused their efforts on the development of patient-specific cellular therapies designed to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. Tovaxin, the company’s lead product candidate, is an innovative T-cell vaccine used to treat MS. Results from the Phase IIb study have shown a positive trend in reducing annualized relapse rate for patients treated with the drug compared to placebo. For further information, visit the Company's web site at www.opexatherapeutics.com.

MondayNov 03, 2008 4:37 am

Bioheart, Inc.’s (NASDAQ: BHRT)

Bioheart, Inc.’s (NASDAQ: BHRT) primary mission is to become a leading company focused on discovering, developing and commercializing innovative, autologous cell therapies and such devices. A number of cell therapies and related devices designed to treat chronic and acute heart damage consist of the company’s product line. They believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant as there are approximately 5.2 million patients with heart failure in the United States alone. For further information, visit the Company's web site at www.bioheartinc.com.

Site Search

Company Search

BioSpecifics Technologies Corp. (OTC BB: BSTC)

Orthovita, Inc. (NASDAQ: VITA)

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)

Origin Agritech Limited (NASDAQ: SEED)

Orexigen Therapeutics, Inc. (NASDAQ: OREX)

Orko Silver Corp. (TSX: OK CN)

Bionovo, Inc. (NASDAQ: BNVI)

Oramed Pharmaceuticals Inc. (OTC BB: ORMP)

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

Bioheart, Inc.’s (NASDAQ: BHRT)

Market Basics

Newsletter Publishers

Public Companies